Knee osteoarthritis (OA) remains a leading cause of chronic pain and reduced mobility, affecting millions of adults worldwide, particularly those over age 50. As cartilage deteriorates and inflammation increases, patients often face pain, stiffness, swelling, and limitations in daily activities. Although no cure exists, a structured, escalating treatment plan can significantly alleviate symptoms, preserve function, delay disease progression, and help many individuals avoid or postpone surgery. Current guidelines from the American Academy of Orthopaedic Surgeons (AAOS, 2021) and the Osteoarthritis Research Society International (OARSI, 2019), along with more recent 2024 to 2025 evidence syntheses, continue to endorse a multimodal, patient-centered strategy that begins with low-risk, non-invasive measures and progresses only as needed.
This article presents a practical, evidence-informed treatment ladder grounded in the latest high-quality research through early 2026. It emphasizes shared decision-making tailored to symptom severity, radiographic grade (e.g., Kellgren-Lawrence), age, comorbidities, activity level, and patient preferences.
Multidisciplinary collaboration among orthopedic surgeons, physical therapists, primary care providers, and pain management specialists optimizes outcomes. For most patients, early intervention with conservative therapies yields meaningful relief; when these fall short, targeted injections, regenerative approaches, or surgery can restore quality of life. Advanced nerve-based interventions offer hope for refractory cases.
The foundation of physical therapy and lifestyle modifications
Effective knee OA management starts with non-pharmacologic strategies that patients can actively control. Structured physical therapy (PT), incorporating aerobic exercise, strengthening, neuromuscular training, flexibility, and sometimes aquatic programs, consistently reduces pain and improves function. A 2025 network meta-analysis of exercise modalities found aerobic exercise likely provides the largest benefits for pain, function, gait, and quality of life in knee OA, with moderate certainty evidence. OARSI guidelines designate land-based exercise (with or without weight management) as a core treatment for nearly all patients.
For those who are overweight or obese, even modest sustained weight loss of 5 to 10 percent through combined diet and exercise dramatically lowers joint loading and pain while enhancing mobility. Recent trials confirm that physiotherapy-delivered diet-plus-exercise programs achieve clinically meaningful weight reduction without compromising gait speed, though pain reduction may be comparable to exercise alone in some cohorts. Patient education on joint protection, activity pacing, and self-management further empowers long-term adherence. Many individuals experience substantial improvement within 3 to 6 months and never require escalation. When symptoms persist despite optimized conservative care, clinicians may introduce injections.
Intra-articular corticosteroid injections for short-term relief
Corticosteroid (cortisone) injections deliver rapid anti-inflammatory effects, often improving pain and function within days for 4 to 12 weeks. Randomized trials and meta-analyses support their short-term superiority over placebo, making them useful for flares or to facilitate continued PT. However, 2025 data highlight limitations: Repeated injections may accelerate cartilage volume loss and radiographic OA progression compared with hyaluronic acid (HA) or controls, though symptomatic benefits remain clinically relevant in the first 1 to 2 months. Guidelines generally limit use to three to four injections per year. These remain a low-cost, insurance-covered option for bridging to longer-term therapies.
Viscosupplementation with hyaluronic acid for modest benefit
Hyaluronic acid (“gel”) injections aim to restore joint lubrication and cushioning, typically administered in one to five weekly doses. While some patients with mild-to-moderate OA report relief lasting up to 6 to 12 months, large reviews and AAOS guidance note only small, often clinically insignificant pain reduction versus placebo. A 2025 comparative study found HA provided superior long-term functional gains compared with corticosteroids in some patients, with no clear difference in radiographic progression or progression to total knee arthroplasty (TKA). Utilization has stabilized after earlier declines, but insurance coverage varies, and it is generally reserved for patients who cannot tolerate steroids or if cortisone injection effect was temporary or prefer non-corticosteroid options.
Regenerative therapies using platelet-rich plasma and stem cells
Patients seeking to delay surgery increasingly turn to autologous or allogeneic regenerative injections. Platelet-rich plasma (PRP) has garnered strong support in 2025 meta-analyses of randomized controlled trials, demonstrating clinically meaningful improvements in pain and function at 6 to 12 months versus placebo, HA, or corticosteroids, particularly with higher platelet concentrations or multiple injections. Complications are similar to other injectables but higher than placebo.
Mesenchymal stem cell (MSC) therapy, often derived from bone marrow or adipose tissue, shows comparable promise. Systematic reviews and meta-analyses from 2025 to 2026 report significant, sometimes durable reductions in pain and improvements in function (e.g., Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] scores), though benefits may wane slightly by 2 years in some patients. These office-based procedures carry low risk (primarily injection-site soreness) but are often self-pay and labeled investigational by payers due to variability in cell preparation and long-term data. They are best positioned after simpler injections fail but before major surgery.
Total knee arthroplasty for end-stage disease
When conservative measures, injections, and regenerative options no longer suffice and particularly in moderate-to-severe OA with substantial structural damage, TKA remains the gold-standard intervention. Prospective 2025 studies confirm dramatic, sustained improvements in pain and function, with Knee Society Scores rising from poor preoperative levels to excellent by 6 months postoperatively in nearly all patients. Satisfaction exceeds 80 to 90 percent, though recovery requires 3 to 6 months of rehabilitation. Risks include infection, stiffness, or revision (approximately 5 to 10 percent at 10 to 15 years). AAOS surgical guidelines underscore preoperative optimization of modifiable factors such as weight, diabetes, and smoking. TKA is reserved for patients whose quality of life is meaningfully impaired.
Refractory pain management with nerve ablation
For patients with persistent pain who are not surgical candidates or prefer to avoid TKA, minimally invasive nerve-targeted procedures provide a bridge. Diagnostic genicular nerve blocks (using local anesthetic, often with steroid) identify candidates for radiofrequency ablation (RFA). 2025 meta-analyses indicate RFA may deliver moderate short-term pain relief (up to 12 weeks) and functional gains compared with sham, particularly with large-lesion techniques, but benefits often diminish by 24 weeks and evidence certainty remains low to moderate. No serious adverse events are typically reported, and the procedure is outpatient and repeatable. It does not alter the joint itself and suits patients seeking non-destructive options.
Peripheral nerve stimulation as a reversible strategy
When pain remains refractory despite RFA or other interventions, peripheral nerve stimulation (PNS) offers a modern, minimally invasive neuromodulation tool that pain specialists increasingly favor. Temporary (often 60-day) or permanent percutaneous leads are placed near target nerves (e.g., genicular or saphenous branches) under imaging guidance. Low-level electrical pulses interrupt pain signals without tissue destruction. Retrospective 2025 analyses report responder rates (50 percent or more pain relief) of 80 to 94 percent in chronic knee OA or post-TKA pain, with average reductions exceeding 70 to 80 percent and decreased opioid use; benefits can persist after stimulation ends. As pain management physicians, we view PNS as safe, adjustable, and particularly valuable for non-surgical candidates or those who have exhausted other steps. It bridges ablation and more invasive spinal devices while preserving joint integrity. Larger trials are ongoing, but real-world outcomes are encouraging.
A logical progression for knee osteoarthritis management
Knee OA management is highly individualized and follows a logical progression: Begin with physical therapy and weight loss, layer in targeted injections or regenerative therapies, consider TKA for advanced disease, and reserve nerve procedures (RFA or PNS) for refractory cases. The latest 2025 to 2026 research reinforces that early, consistent conservative care works for most patients, while emerging regenerative and neuromodulation options expand non-surgical horizons. Shared decision-making, regular reassessment, and attention to modifiable factors remain essential. Patients struggling with knee pain should seek prompt evaluation as many effective pathways exist to restore mobility and improve daily life.
Kayvan Haddadan is a physiatrist and pain management physician, and president and medical director of Advanced Pain Diagnostic & Solutions, a multidisciplinary pain management practice in California that he founded in 2012. A physician and surgeon licensed by the Medical Board of California, he is double board-certified in pain medicine and physical medicine and rehabilitation. He is also certified in controlled substance registration through the DEA and serves as a qualified medical examiner through California’s Department of Industrial Relations Division of Workers’ Compensation.
Dr. Haddadan earned his Bachelor of Science degree from the College of Alborz in Tehran, Iran, and his medical degree from Shahid Beheshti University of Medical Sciences. He later received his Educational Commission for Foreign Medical Graduates certification in Philadelphia, completed an internship in medical surgery at Loyola University Medical Center’s Stritch School of Medicine in Illinois, and finished his residency in physical medicine and rehabilitation at the same institution. He completed his fellowship in pain medicine at California Pacific Medical Center’s Pacific Pain Treatment Center and also trained in medical acupuncture for physicians at the University of California, Los Angeles David Geffen School of Medicine.
Dr. Haddadan has contributed to 29 research publications across multiple specialties, including pain management, cardiology, pulmonology, endocrinology, gastroenterology, and infectious disease. His work has examined topics such as hyperlipidemia in high cardiovascular risk patients, hyperuricemia and gout management, type 2 diabetes and hypertension, chronic obstructive pulmonary disease and asthma therapies, influenza treatment, irritable bowel syndrome, and opioid related complications in chronic pain care. His research has also included clinical outcome studies in spinal cord stimulation and award-winning presentations on neuropathic pain management and neuromuscular disorders.
